 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...184185186187188189190191192193194...235236» |
- | Enrollment closed, Trial primary completion date: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Jan 18, 2018
P2, N=25, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Aug 2017
- | Sotyktu (deucravacitinib) / BMS
New P1 trial: A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (clinicaltrials.gov) - Jan 18, 2018
P1, N=12, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy (clinicaltrials.gov) - Jan 17, 2018
P3, N=2660, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Aug 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Jan 17, 2018
P3, N=162, Active, not recruiting, Sponsor: The Christie NHS Foundation Trust
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> Jan 2018
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (clinicaltrials.gov) - Jan 16, 2018
P2, N=32, Not yet recruiting, Sponsor: University of Saskatchewan
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Surgery: Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (clinicaltrials.gov) - Jan 16, 2018
P2, N=46, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> Jan 2018 Trial primary completion date: Dec 2018 --> Dec 2019
- | Avastin (bevacizumab) / Roche
Trial primary completion date: APPROACH: Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets (clinicaltrials.gov) - Jan 12, 2018
P2, N=218, Active, not recruiting, Sponsor: Yonsei University
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Aug 2017 --> May 2018
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Jan 12, 2018
P3, N=580, Recruiting, Sponsor: Yonsei University
Trial primary completion date: Aug 2017 --> May 2018 Trial primary completion date: May 2018 --> May 2019
- | Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Jan 12, 2018
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial primary completion date: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Jan 11, 2018
P2, N=65, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Feb 2018 --> May 2018
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 11, 2018
P1, N=34, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Feb 2018 --> May 2018 Trial primary completion date: Dec 2017 --> Nov 2018
- rosmantuzumab (OMP-131R10) / Mereo Biopharma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Jan 11, 2018
P1, N=50, Active, not recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Trial primary completion date: Dec 2017 --> Nov 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Apr 2018
- | Enrollment closed, Trial primary completion date: COLOPEC: Adjuvant HIPEC in High Risk Colon Cancer (clinicaltrials.gov) - Jan 10, 2018
P3, N=204, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2019 --> Sep 2018
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (clinicaltrials.gov) - Jan 10, 2018
P1, N=31, Completed, Sponsor: Aslan Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2019 --> Sep 2018 Recruiting --> Completed | N=24 --> 31 | Trial primary completion date: Dec 2017 --> Jun 2017
- carfilzomib / Generic mfg.
Trial primary completion date: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Jan 9, 2018
P1, N=21, Recruiting, Sponsor: University of California, Davis
Recruiting --> Completed | N=24 --> 31 | Trial primary completion date: Dec 2017 --> Jun 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | Vectibix (panitumumab) / Amgen
Enrollment open: TRIPLETE: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (clinicaltrials.gov) - Jan 9, 2018
P3, N=432, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- bemarituzumab (AMG 552) / Amgen
Enrollment open, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (clinicaltrials.gov) - Jan 9, 2018
P1, N=21, Recruiting, Sponsor: Five Prime Therapeutics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Aphexda (motixafortide) / BioLineRx, Ayrmid
Enrollment closed, Enrollment change, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Jan 9, 2018
P2, N=37, Active, not recruiting, Sponsor: BioLineRx, Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 37
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: TRUST: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (clinicaltrials.gov) - Jan 9, 2018
P2, N=49, Active, not recruiting, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Recruiting --> Active, not recruiting | N=30 --> 37 Trial primary completion date: Apr 2017 --> Jul 2017
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Combination therapy: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov) - Jan 9, 2018
P1, N=25, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Apr 2017 --> Jul 2017 Not yet recruiting --> Recruiting
- |||| Enrollment open, Metastases: PANTHEON: A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy (clinicaltrials.gov) - Jan 8, 2018
P2, N=204, Recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Enrollment open: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Jan 8, 2018
P3, N=5956, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- Enrollment closed, Enrollment change, Trial initiation date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Jan 8, 2018
P1/2, N=3, Active, not recruiting, Sponsor: NantKwest, Inc.
Suspended --> Recruiting Recruiting --> Active, not recruiting | N=80 --> 3 | Initiation date: Dec 2017 --> Aug 2017
- ||| Enrollment closed: QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Jan 8, 2018
P1/2, N=80, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting | N=80 --> 3 | Initiation date: Dec 2017 --> Aug 2017 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Journal: Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer. (Pubmed Central) - Jan 5, 2018
Recruiting --> Active, not recruiting Bev, in the combination that was used in this study, meets response, survival, and toxicity criteria for further testing against second- or multi-line chemotherapy-resistant tumors and also when a standard treatment is not safe.
- | Clinical, Review, Journal: Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. (Pubmed Central) - Jan 5, 2018
Data from phase III studies combining SIRT with fluorouracil (5FU) or folinic acid/5FU/oxaliplatin (FOLFOX) suggest that hematological toxicity is more common from the combination than it is from chemotherapy without SIRT. There is no evidence to suggest that chemotherapy increases SIRT-specific gastro-intestinal or liver toxicities.
- | Erbitux (cetuximab) / Eli Lilly, cetuximab biosimilar / CinnaGen
New P3 trial, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 5, 2018
P3, N=234, Not yet recruiting, Sponsor: Cinnagen
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 5, 2018
P2, N=100, Active, not recruiting, Sponsor: RenJi Hospital
- | Enrollment open, Metastases: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 3, 2018
P2, N=100, Recruiting, Sponsor: RenJi Hospital
There is no evidence to suggest that chemotherapy increases SIRT-specific gastro-intestinal or liver toxicities. Active, not recruiting --> Recruiting
- | New P2 trial: SENECA: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas (clinicaltrials.gov) - Jan 2, 2018
P2, N=112, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- | oxaliplatin / Generic mfg.
New P2 trial: METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (clinicaltrials.gov) - Jan 2, 2018
P2, N=100, Not yet recruiting, Sponsor: University Hospital, Akershus
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=47, Recruiting, Sponsor: Centre Jean Perrin
Active, not recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Jun 2019
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=79, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Jul 2017 --> Jun 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | Vectibix (panitumumab) / Amgen
New P3 trial: TRIPLETE: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (clinicaltrials.gov) - Dec 29, 2017
P3, N=432, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial withdrawal, PD(L)-1 Biomarker, IO biomarker: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (clinicaltrials.gov) - Dec 29, 2017
P2, N=0, Withdrawn, Sponsor: Weijing Sun, MD, FACP
Trial primary completion date: Dec 2017 --> Dec 2018 N=40 --> 0 | Terminated --> Withdrawn
- | veliparib (ABT-888) / AbbVie
New P1/2 trial, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=48, Recruiting, Sponsor: Georgetown University
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=110, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- ||||| New P1/2 trial: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=173, Recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=65, Recruiting, Sponsor: NantKwest, Inc.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial initiation date, Trial termination, Trial primary completion date, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Dec 29, 2017
P2, N=2, Terminated, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
N=40 --> 0 | Terminated --> Withdrawn Initiation date: Jan 2015 --> Sep 2015 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Jan 2016
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 26, 2017
P2, N=56, Active, not recruiting, Sponsor: Children's Oncology Group
Initiation date: Jan 2015 --> Sep 2015 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Jan 2016 Recruiting --> Active, not recruiting
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 22, 2017
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jul 2018
- |||| numidargistat (INCB001158) / Calithera
Enrollment open, Combination therapy, Metastases: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Dec 22, 2017
P1/2, N=249, Recruiting, Sponsor: Incyte Corporation
Trial primary completion date: Jan 2018 --> Jul 2018 Not yet recruiting --> Recruiting
- | Journal: A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. (Pubmed Central) - Dec 21, 2017
He received six months of neoadjuvant therapy including FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and stereotactic body radiation therapy (SBRT) to the pancreatic tumor followed by a combined pancreaticoduodenectomy and Ivor Lewis esophagectomy...Extensive evaluation and continued follow-up of PDAC patients presenting with a synchronous esophageal lesion in a multidisciplinary setting may help ensure efficient and accurate management. In our case, neoadjuvant FOLFIRINOX and SBRT to the primary PDAC tumor followed by surgery has been an effective approach for this patient.
- |||||||||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P3 trial, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2017
P3, N=645, Recruiting, Sponsor: Array BioPharma
- |||| cabiralizumab (BMS-986227) / Ono Pharma, BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial primary completion date: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 20, 2017
P2, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
In our case, neoadjuvant FOLFIRINOX and SBRT to the primary PDAC tumor followed by surgery has been an effective approach for this patient. Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2020 --> Dec 2020
- | Avastin (bevacizumab) / Roche
Biomarker, New P3 trial: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Dec 19, 2017
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial termination, Metastases: Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 19, 2017
P1/2, N=24, Terminated, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2020 --> Dec 2020 Active, not recruiting --> Terminated; Due to slow accrual
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Metastases: Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 19, 2017
P3, N=32, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Terminated; Due to slow accrual N=380 --> 32 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Nov 2014; Slow accrual